Morris Karmazyn

Professor

Morris Karmazyn


Canada Research Chair in Experimental Cardiology
PH.D.
McGill University
M.Sc. McGill University
B.Sc. Loyola College
Office:  Medical Sciences Building, Room 252
Phone: (519) 661-3872
Fax:  (519) 661-3827
E-mail: morris.karmazyn@schulich.uwo.ca
See Publications by Morris Karmazyn on PubMed

The primary research in my laboratory involves the understanding of the mechanisms of cardiac hypertrophy and heart failure and development of novel therapeutic strategies. 

We are currently studying the cellular and molecular bases for heart failure with the ultimate aim of developing effective therapeutic strategies. Heart failure is an extremely complex syndrome underlined by a large number of molecular, cellular and structural changes which occur over a prolonged period of time, a process known as myocardial remodelling. We use multifaceted approaches to study the myocardial remodelling process. For example, using cultured rat ventricular myocytes we are studying the molecular bases for induction of hypertrophy and the role of key genes in this process. We are also utilizing animal models including the rat myocardial infarction model to assess the effects of novel approaches on the postinfarction hypertrophic process. Taken together, our laboratory offers the opportunity to investigate heart failure using multifaceted approaches that offers an excellent training experience.  

Our laboratory has currently a number of ongoing projects which are funded either by the Heart and Stroke Foundation of Ontario or the Canadian Institutes of Health Research. These areas include:  1) Role of intracellular sodium dysregulation in myocardial in myocardial remodelling; 2) Role of the obesity-related peptide in myocardial remodelling; 3) Role of adenosine in myocardial remodelling; 4) Role of nitric oxide in myocardial remodelling; 4) Role of epoxygenase-derived arachidonic acid metabolites in myocardial remodelling and 5) The potential benefit of ginseng on myocardial remodelling.

Selected recent publications:  

Moey M, Gan XT, Xiaoling Huang C, Rajapurohitam V, Martínez-Abundis E, Lui EM, Karmazyn M. Ginseng reverses established cardiomyocyte hypertrophy and post myocardial infarction-induced hypertrophy and heart failure. Circ Heart Fail. 2012 May 10. [Epub ahead of print]

Rajapurohitam V, Kilic A, Javadov S, Karmazyn M. Role of NF-κB and p38 MAPK activation in mediating angiotensin II and endothelin-1-induced stimulation in leptin production and cardiomyocyte hypertrophy. Mol Cell Biochem 366: 287-297, 2012.

Moey M, Rajapurohitam V, Zeidan A, Karmazyn M. Ginseng (Panax quinquefolius) attenuates leptin-induced cardiac hypertrophy through inhibition of p115Rho guanine nucleotide exchange factor-RhoA/Rho-associated, coiled-coil containing protein kinase-dependent mitogen-activated protein kinase pathway activation. J Pharmacol Exp Ther 339: 746-56, 2011. 

Karmazyn M, Moey M, Gan XT. Therapeutic potential of ginseng in the management of cardiovascular disorders.  Drugs 71:1989-2008, 2011. 

Javadov S, Rajapurohitam V, Kilić A, Hunter JC, Zeidan A, Said Faruq N, Escobales N, Karmazyn M. Expression of mitochondrial fusion-fission proteins during post-infarction remodeling: the effect of NHE-1 inhibition.  Basic Res Cardiol 106:99-109, 2011. 

Kilic A, Rajapurohitam V, Sandberg SM, Zeidan A, Hunter JC, Said Faruq N, Lee CY, Burnett JC Jr, Karmazyn M. A novel chimeric natriuretic peptide reduces cardiomyocyte hypertrophy through the NHE-1-calcineurin pathway. Cardiovasc Res 88: 434-42, 2010. 

Pang T, Gan XT, Freeman DJ, Cook MA, Karmazyn M. Compensatory upregulation of the adenosine system following phenylephrine-induced hypertrophy in cultured rat ventricular myocytes. Am J Physiol Heart Circ Physiol 298: H545-H553, 2010.




Innovation and Excellence in Research and Teaching